Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OxyPLEASURE: Intranasal Oxytocin for Sexual Well-Being in AVP Deficiency
NCT06808516Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of oxytocin nasal spray in arginine vasopressin deficiency (CDI), sponsored by University Hospital Basel. Started Jul 2025; status: recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
arginine vasopressin deficiency (CDI)
Beyond the preview
Go deeper on NCT06808516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808516.